Leonard Blum currently serves as EyePoint’s Executive Vice President and General Manager, U.S. Mr. Blum brings to EyePoint more than 30 years of successful executive and management experience, most recently serving as Chief Business and Commercial Officer of Omeros Corporation, where he oversaw sales and marketing efforts for OMIDRIA®, a product used by ophthalmologists in conjunction with cataract surgery and intraocular lens replacement to maintain pupil size and reduce postoperative pain. Prior to joining Omeros in 2016, he served as Senior Vice President, Chief Commercial Officer at Theravance, Inc., a publicly traded biopharmaceutical company, and its spin-off company, Theravance BioPharma, from 2007 until 2016. In this capacity, he collaborated with Astellas Pharma in the launch of VIBATIV®, a drug for the treatment of hospital-acquired bacterial pneumonia and complicated skin and soft structure infections, and with Glaxo SmithKline in the launches of BREO® and ANORO®, two combination therapies for the treatment of chronic obstructive pulmonary disease and asthma. Prior to that, Mr. Blum founded and led the commercial functions at ICOS Corporation, a biotechnology company, progressing from Vice President, Marketing to Senior Vice President, Sales and Marketing, from 2000 until the company’s acquisition by Eli Lilly and Company in 2007. At ICOS, he was responsible for the launch and commercialization of CIALIS®, which is the worldwide top-selling treatment for erectile dysfunction.
Mr. Blum began his career in the pharmaceutical industry at Merck & Co., where he spent thirteen years in positions of increasing responsibility in marketing and business unit leadership in the U.S. and Europe. Over these years, Mr. Blum was responsible for more than a dozen product launches in several therapeutic categories and markets.
Mr. Blum earned his A.B. in Economics, magna cum laude, at Princeton University, studied International Finance on a Fulbright Fellowship at the University of Zurich and completed an M.B.A. at Stanford University’s Graduate School of Business. Before entering the pharmaceutical industry, Mr. Blum served as an officer in the U.S. Army Special Forces and completed his military service at the rank of Captain.